复方藤梨根制剂辅助化疗治疗晚期结肠癌脾虚证62例回顾性研究  

Retrospective Study on Compound Actinidia Arguta(藤梨根) Preparation Adjuvant Chemotherapy in Treating 62 Cases of Advanced Colon Cancer with Spleen Deficiency Syndrome

作　　者：董晶 施航 DONG Jing;SHI Hang(Ningbo City Hospital of Traditional Chinese Medicine,Zhejiang 315010)

机构地区：[1]浙江省宁波市中医院

出　　处：《中医杂志》2018年第15期1310-1313,共4页Journal of Traditional Chinese Medicine

基　　金：浙江省中医药科技计划项目(2012ZA112);国家中医药管理局"十二五"重点专科建设项目(国中医药医政发[2012]2号)

摘　　要：目的评价中药复方藤梨根制剂辅助化疗治疗晚期结肠癌脾虚证临床疗效并分析影响患者无进展生存期的相关因素。方法回顾性分析2013年6月至2016年6月宁波市中医院肿瘤科收治的62例晚期结肠癌脾虚证患者,所有患者接受复方藤梨根制剂口服每日1剂,同时联合XELOX或FOLFIRI方案化疗,以42天为1个疗程,治疗至出现病情进展。治疗前及治疗1个疗程后进行中医症状评分,包括食少纳呆、体倦乏力、腹胀、大便异常;观察患者无进展生存期并进行其影响因素分析;治疗1个疗程后评价近期临床疗效、中医证候疗效和生活质量疗效。结果治疗1个疗程后各中医症状评分均明显低于治疗前(P<0.05)。治疗1个疗程后患者近期临床疗效客观有效率为58.1%,临床受益率为82.3%;中医证候疗效:显效34例,有效15例,无效13例;生活质量疗效:显著改善10例,改善25例,稳定14例,下降13例。患者中位无进展生存期为28周,单因素分析显示,无进展生存期与既往有根治性手术、癌转移数目、内脏转移、转移脏器相关(P<0.05);多因素分析显示,患者癌转移数目每增多一个进展风险高5.733倍,有内脏转移比无内脏转移进展风险高10.100倍,转移的脏器每多一个进展风险增加1.680倍。结论复方藤梨根制剂辅助化疗治疗晚期结肠癌脾虚证患者近期临床疗效有效率高达58.1%,癌转移数目少、无内脏转移、转移脏器较少的患者无进展生存期更长。Objective To evaluate the clinical efficacy of Chinese medicine compound Actinidia arguta（ 藤梨根） preparation adjuvant chemotherapy in the treatment of advanced colon cancer with spleen deficiency,and to analyze the related factors affecting the progression-free survival of patients. Methods A retrospective analysis of 62 patients with advanced colon cancer admitted to the Department of Oncology,Ningbo City Hospital of Traditional Chinese Medicine from June 2013 to June 2016 was conducted. All patients received a daily dose of compound Actinidia arguta preparation and combined with XELOX or FOLFIRI regimen chemotherapy,with 42 days as a course of treatment,until the disease progresses. Traditional Chinese medicine（ TCM） syndrome scores were evaluated before treatment and after 1 course of treatment,including food intake,body fatigue,abdominal distension,and stool abnormalities; the progression-free survival of patients was observed and its influencing factors were analyzed; The shortterm clinical efficacy,TCM syndrome efficacy and quality of life efficacy after 1 course of treatment were evaluated.Results The scores of TCM syndromes were significantly lower after treatment for 1 course of treatment（ P〈0. 05）.After 1 course of treatment,the patient ＇s short-term clinical efficacy was 58. 1%,and the clinical benefit rate was82. 3%. TCM syndrome efficacy： 34 cases were markedly effective,15 cases were effective,13 cases were ineffective. Efficacy on quality of life： 10 cases were significantly improved,25 cases were improved,14 cases were stable and 13 cases were decreased. The median progression-free survival was 28 weeks. Univariate analysis showed that progression-free survival was associated with previous radical surgery,number of cancer metastases,visceral metastasis,and metastatic organ（ P〈0. 05）. Multivariate analysis showed that the progression risk was increased by 5. 733 times for each increase of number of cancer metastasis,and the risk of visceral metastasis was 10. 100 time

关 键 词：晚期结肠癌 脾虚证 复方藤梨根制剂 化疗 无进展生存期 

分 类 号：R735.35[医药卫生—肿瘤]